Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer

BACKGROUND: Large scale randomized controlled trials have demonstrated that the use of bevacizumab in addition to chemotherapy in patients with advanced non‐small cell lung cancer (NSCLC) conveys significant survival benefits. We explored the clinical impact of a first‐line regimen containing bevaci...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Thorac Cancer
Главные авторы: Xing, Puyuan, Mu, Yuxin, Wang, Yan, Hao, Xuezhi, Zhu, Yixiang, Hu, Xingsheng, Wang, Hongyu, Liu, Peng, Lin, Lin, Wang, Zhijie, Li, Junling
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons Australia, Ltd 2018
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026612/
https://ncbi.nlm.nih.gov/pubmed/29768721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12650
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы